On Grindeks audited financial results for 2013

On Grindeks audited financial results for 2013


Today, on 30 April, JSC Grindeks has submitted the audited consolidated financial statements for 2013 to “Nasdaq OMX Riga”. Audited financial results show that the Group’s turnover amounted to 118.5 million euros in 2013, which is by 0.8 million euros or 1% more than in 2012.

In its turn, net profit related to the shareholders of the holding company amounted to 13.4 million euros in 2013 . In 2013, gross profit margin of the Group was 60%, whereas, net profit margin comprised to 11.3%. Products of the Group, manufactured in 2013, were exported to 59 countries worldwide for the total amount of 112.4 million euros, which is by 1.2 million euros or by 1.1% more than in 2012.
In 2013, ROE was 11.9%; ROA was 9.3%; ROS was 13.9%; liquidity was 3.6.
Sales volume of the final dosage forms of Grindeks in 2013 was 100.3 million euros and has increased by 0.8 million euros or 1% in comparison to 2012. The sales amount in Russia, other CIS countries and Georgia reached 86.7 million euros in 2013, which is by 0.9 million euros or 1% more than in 2012. In its turn, turnover of the final dosage forms in the Baltic States and other European countries was 13.6 million euros, which is by 0.1 million euros or 0.4% less than in 2012. The most demanded products of Grindeks in 2013 were the brand product Mildronate®, ointments – Capsicam®, Viprosal B®, central nervous system medication – Somnols®, the original anti-cancer medication Ftorafur® and natural product Apilak-Grindeks.
In 2013, sales of the active pharmaceutical ingredients reached 18 million euros, which is by 0.1 million lats or 0.4% more than in 2012. Overall Grindeks produces 25 active pharmaceutical ingredients.
JSC Grindeks Chairman of the Board Juris Bundulis: “Grindeksconcluded the year of 2013 with turnover of 118.46 million euros and profit of 13.834 million euros. Considering fierce competition in the pharmaceuticals market, these achievements are remarkable. In order to deliver the most appropriate solution to each patient, in 2014 Grindeks intends to improve its operating model, previously focused on the best-selling products, to a broader set of products and services. We have wide network of Grindeks representative offices, accordingly we will follow to customize specific needs of each region. I am convinced that these novations will improve the performance of company. Grindeks has always been the long-term development-oriented company, and therefore we will also continue to invest in both product portfolio development and acquisition of new markets.”
To secure and increase the understanding of investors, cooperation partners, clients and society about the company, its activities and governance, Grindeks audited consolidated financial statement of 2013 is submitted to “Nasdaq OMX Riga” together with Corporate Governance Report of the year of 2013.

JSC Grindeks audited financial statements of 2013. (879 KB)

JSC Grindeks corporate governance report of 2013. (163 KB)

Related posts


Grindeks celebrates 75-year anniversary

Today on December 21, JSC Grindeks, the leading pharmaceutical manufacturer in the Baltic States celebrates its 75-year anniversary. Over these 75 years, Grindeks has become...